openPR Logo
Press release

Creative Diagnostics Announces the Launch of Norovirus VLP Antigens to Support Vaccine Research

05-21-2024 07:02 PM CET | Health & Medicine

Press release from: ABNewswire

Creative Diagnostics Announces the Launch of Norovirus VLP

Creative Diagnostics announces its new line of Norovirus VLP Antigens for in vitro diagnostics and vaccine research.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is pleased to announce the availability of its new line of Norovirus VLP Antigens [https://www.creative-diagnostics.com/new-norovirus-vlp-antigens.htm] to accelerate in vitro diagnostics and vaccine research. These new antigens have been validated to a high level of confidence using electron microscopy.

Norovirus is a non-enveloped, positive-sense, single-stranded RNA virus of the family Caliciviridae and is the leading cause of non-bacterial acute gastroenteritis worldwide. The infection is characterized by non-bloody diarrhea, vomiting and abdominal pain. The stability of viral particles is of particular interest because noroviruses are transmitted by the fecal-oral route and they can persist in the environment. Studies of the assembly and degradation of norovirus capsids have relied heavily on norovirus-like particles.

The norovirus genome is 7.4-7.7 kb in size and has three open reading frames (ORFs). Nonstructural proteins, such as RNA-dependent polymerase (RdRp), are encoded by ORF1, while structural proteins are encoded by ORF2 (VP1) and ORF3 (VP2). Structural analysis of noroviruses has shown that each viral capsule consists of 90 dimers of VP1 with T = 3 icosahedral symmetry. Various expression systems have been developed to produce viral capsids in the form of virus-like particles (VLPs).

Noroviruses are classified into genomic groups and genotypes based on the amino acid diversity of the VP1 protein. According to this system, the genus Norovirus is divided into 10 genomes (GI-GX) and 49 genotypes (9 GI, 27 GII, 3 GIII, 2 GIV, 2 GV, 2 GVI, and 1 each of GVII, GVIII, GIX [formerly GII.15 ], and GX), of which the genomes known to be infectious to humans include GI, GII, GVIII, and GIX. GII.4 is of particular importance as it has caused numerous outbreaks worldwide over the years and is believed to be the primary cause of human infections.

Creative Diagnostics now offers a series of yeast-expressed Norovirus VLP antigens for in vitro diagnostic and vaccine studies, including Recombinant Norovirus GI.1 VLP, Recombinant Norovirus GII.3 VLP, and Recombinant Norovirus GII.17 VLP. These antigens have been validated with high confidence by electron microscopy and provide researchers and diagnosticians with a powerful tool for studying and detecting Norovirus infections. Creative Diagnostics' team of experts is also available to assist researchers in selecting the most suitable antigens for their specific studies.

The purified Norovirus VLP Antigens are an example of Creative Diagnostics' commitment to providing innovative and reliable products to the research and diagnostic communities. Its team has worked diligently to develop antigens that are not only highly specific but also offer excellent sensitivity, making them ideal for a wide range of diagnostic and research applications.

Creative Diagnostics offers a comprehensive range of Norovirus VLP Antigens catering to diverse research needs. For more information on the new antigens, please visit https://www.creative-diagnostics.com/new-norovirus-vlp-antigens.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers' assay development and manufacturing needs.

Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=creative-diagnostics-announces-the-launch-of-norovirus-vlp-antigens-to-support-vaccine-research]
State: New York
Country: United States
Website: https://www.creative-diagnostics.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Diagnostics Announces the Launch of Norovirus VLP Antigens to Support Vaccine Research here

News-ID: 3506674 • Views:

More Releases from ABNewswire

Qixas Group Ranked #1 Microsoft Dynamics Partner in Canada
Qixas Group Ranked #1 Microsoft Dynamics Partner in Canada
Qixas Group has been ranked the #1 Microsoft Dynamics Partner in Canada by Top Dynamics Partners. Recognized for customer success, Dynamics 365 expertise, and market leadership, Qixas continues to drive digital transformation across industries. Toronto, Canada - October 29, 2025 - Qixas Group [https://qixas.com/], a leading provider of Microsoft Dynamics 365 solutions, has been named the #1 Microsoft Dynamics Partner in Canada by Top Dynamics Partners [https://topdynamicspartners.com/]. This recognition highlights Qixas
Drones, Data, and Defense: The $555 Billion Market Reshaping Aerospace (ZENA, AVAV, KTOS, LHX)
Drones, Data, and Defense: The $555 Billion Market Reshaping Aerospace (ZENA, AV …
Autonomous systems and AI-powered drones are reshaping operations across government, defense, and commercial sectors. The global drone market is projected to surpass $555 billion by 2034, with U.S. commercial and defense applications driving the majority of growth. Within that, Drone as a Service (DaaS) is gaining traction as organizations adopt flexible, on-demand models that eliminate capital investment, pilot staffing, and regulatory hurdles. Analysts expect the U.S. DaaS market to grow
Healthcare Triangle (NASDAQ: HCTI): Targeting $573 Billion Digital Health Market with AI-Driven Platform
Healthcare Triangle (NASDAQ: HCTI): Targeting $573 Billion Digital Health Market …
The healthcare technology market is undergoing rapid transformation, fueled by rising demand for digital patient engagement, AI-powered workflow automation, and scalable mental health solutions. Globally, digital health is projected to surpass $550 billion by 2028, with AI-driven platforms commanding an increasingly large share. Within that, mental health alone represents a $448 billion global market, affecting more than 60 million adults in the U.S. Hospitals and health systems are responding by
Dr Ekta's Pain Management Clinic aims to strengthen pain care delivery in Delhi
Dr Ekta's Pain Management Clinic aims to strengthen pain care delivery in Delhi
The Delhi-based clinic, by offering highly innovative and targeted non-surgical pain treatments, aims to help patients receive quality pain treatment and live a pain-free active life. In a move to extend comprehensive pain care services and enable better access to quality pain treatment in capital New Delhi, Dr Ekta's Pain Management clinic, a specialized pain management clinic in Rajouri Garden, West Delhi [https://www.drektapainmanagement.com], introduces a series of highly-sophisticated non-surgical pain treatments

All 5 Releases


More Releases for Norovirus

Norovirus Diagnostics Market Trends and Forecast 2033
Introduction The norovirus diagnostics market has been gaining momentum as the incidence of norovirus infections, commonly referred to as the "winter vomiting bug," increases globally. Norovirus is a highly contagious virus that causes gastroenteritis, leading to symptoms like vomiting, diarrhea, and stomach pain. Its rapid spread, particularly in closed environments like hospitals, nursing homes, schools, and cruise ships, has made timely and accurate diagnostics critical for effective disease management. The global
Norovirus ELISA Kits Market Outlook, Growth Opportunities, Trends, Forecast Repo …
Los Angeles, USA - The global Norovirus ELISA Kits Market is set to undergo significant transformations, as detailed in the latest industry report. This comprehensive analysis equips market participants with critical insights to excel in a competitive landscape by focusing on growth, sales, and other key performance indicators. The report emphasizes emerging opportunities, evolving market trends, and essential dynamics such as market drivers and challenges that will shape the future
Norovirus Treatment Market Size, Share, Trends, Demand, Growth and Competitive A …
Global Norovirus treatment Market report puts light on analysis of prime manufacturers, trends, opportunities, marketing strategies analysis, market effect factor analysis and consumer needs by major regions, types, and applications globally. Market research analysis and insights covered in the comprehensive Norovirus treatment market report are very considerate for the businesses to make better decisions, to develop better strategies about production, marketing, sales and promotion of a particular product and thereby extending
Immersive Technology to guide the growth of Norovirus Diagnostics Market
The Norovirus Diagnostics Market taught to grow sporadically shortly. With improvement in machine-powered analytics, the healthcare vertical is bound to substantiate therein. Machine learning does make caregivers able of putting data to use, thereby enhancing patients’ outcomes along with overall efficiency. This would be the trend in the healthcare vertical going forward. As per Persistence Market Research’s latest industry analysis, the global norovirus diagnostics market was valued at US$ 47.6 Mn
Crowdsourcing of data to drive the Norovirus Diagnostics Market
The Norovirus Diagnostics Market is likely to scintillate going forward. With various cloud options to explore, the healthcare industry is expected to be at a newer high in the forecast period. In other words, organizations across the globe are advancing their downtime regarding digital business initiatives. They are swiftly moving towards the cloud for modernizing the environments, enhancing system reliability, supporting hybrid work models, and addressing the other new-fangled realities
Crowdsourcing of data to drive the Norovirus Diagnostics Market
The Norovirus Diagnostics Market is likely to scintillate going forward. With various cloud options to explore, the healthcare industry is expected to be at a newer high in the forecast period. In other words, organizations across the globe are advancing their downtime regarding digital business initiatives. They are swiftly moving towards the cloud for modernizing the environments, enhancing system reliability, supporting hybrid work models, and addressing the other new-fangled realities